2p4y

Revision as of 12:15, 23 January 2008 by OCA (talk | contribs) (New page: left|200px<br /><applet load="2p4y" size="350" color="white" frame="true" align="right" spinBox="true" caption="2p4y, resolution 2.25Å" /> '''Crystal structure of...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Crystal structure of human PPAR-gamma-ligand binding domain complexed with an indole-based modulator

File:2p4y.jpg


2p4y, resolution 2.25Å

Drag the structure with the mouse to rotate

OverviewOverview

Despite their proven antidiabetic efficacy, widespread use of peroxisome, proliferator-activated receptor (PPAR)gamma agonists has been limited by, adverse cardiovascular effects. To overcome this shortcoming, selective, PPARgamma modulators (SPPARgammaMs) have been identified that have, antidiabetic efficacy comparable with full agonists with improved, tolerability in preclinical species. The results of structural studies, support the proposition that SPPARgammaMs interact with PPARgamma, differently from full agonists, thereby providing a physical basis for, their novel activities. Herein, we describe a novel PPARgamma ligand, SPPARgammaM2. This compound was a partial agonist in a cell-based, transcriptional activity assay, with diminished adipogenic activity and an, attenuated gene signature in cultured human adipocytes. X-ray, cocrystallography studies demonstrated that, unlike rosiglitazone, SPPARgammaM2 did not interact with the Tyr473 residue located within helix, 12 of the ligand binding domain (LBD). Instead, SPPARgammaM2 was found to, bind to and activate human PPARgamma in which the Tyr473 residue had been, mutated to alanine (hPPARgammaY473A), with potencies similar to those, observed with the wild-type receptor (hPPARgammaWT). In additional, studies, we found that the intrinsic binding and functional potencies of, structurally distinct SPPARgammaMs were not diminished by the Y473A, mutation, whereas those of various thiazolidinedione (TZD) and non-TZD, PPARgamma full agonists were reduced in a correlative manner. These, results directly demonstrate the important role of Tyr473 in mediating the, interaction of full agonists but not SPPARgammaMs with the PPARgamma LBD, thereby providing a precise molecular determinant for their differing, pharmacologies.

About this StructureAbout this Structure

2P4Y is a Single protein structure of sequence from Homo sapiens with and as ligands. Full crystallographic information is available from OCA.

ReferenceReference

The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities., Einstein M, Akiyama TE, Castriota GA, Wang CF, McKeever B, Mosley RT, Becker JW, Moller DE, Meinke PT, Wood HB, Berger JP, Mol Pharmacol. 2008 Jan;73(1):62-74. Epub 2007 Oct 16. PMID:17940191

Page seeded by OCA on Wed Jan 23 11:15:15 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA